Beranda › Tumor Neuroendokrin › California
Uji klinis Tumor Neuroendokrin di California
14 studi untuk Tumor Neuroendokrin mencari peserta di lokasi di California.
Kota di California
- San Francisco5 studi
- Mountain View5 studi
- Los Angeles5 studi
- Baldwin Park4 studi
- Orange3 studi
- San Diego3 studi
Teks studi resmi (Bahasa Inggris)
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Cedars-Sinai Medical Center, Beverly Hills
- Norris Comprehensive Cancer Center, Los Angeles
- Stanford Cancer Center, Palo Alto
- dan 2 lainnya
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT06943755Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- UCSF Benioff Children's Hospital, San Francisco
Menerima pesertaFase 1
24 Months – 18 Years · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06441331Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
- Hoag Memorial Hospital Presbyterian, Newport Beach
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07087054Project: Every Child for Younger Patients With Cancer
- Kaiser Permanente Downey Medical Center, Downey
- City of Hope Comprehensive Cancer Center, Duarte
- Loma Linda University Medical Center, Loma Linda
- dan 15 lainnya
Menerima pesertaStudi observasional
Hingga usia 25 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT02402244A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
- Crinetics Study Site, Duarte
- Crinetics Study Site, Newport Beach
- Crinetics Study Site, Orange
- dan 1 lainnya
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT07129252CapTemY90 for Grade 2/3 NET Liver Metastases
- UC San Diego, La Jolla
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Jun 2026 · NCT04339036A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- St Joseph Heritage Healthcare, Santa Rosa
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 27 Mei 2026 · NCT03093116Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
- Stanford University, Palo Alto
Menerima pesertaFase 1/2
Usia 20 hingga 99 · Semua jenis kelamin · Diperbarui 20 Apr 2026 · NCT02174549Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
- Research Facility, Irvine
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Mar 2026 · NCT05477576Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
- City of Hope, Duarte
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
- Stanford Cancer Institute, Stanford
Menerima pesertaFase 1
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 17 Mar 2026 · NCT04119024Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
- University of California, San Francisco, San Francisco
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Mar 2026 · NCT05746208Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
- Cedars-Sinai Medical Center, Los Angeles
Menerima peserta
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 20 Feb 2026 · NCT04907643A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- University of Southern California, Los Angeles
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Des 2025 · NCT06943521SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duarte
- Massive Bio SYNERGY-AI site, Irvine
- Massive Bio SYNERGY-AI site, La Jolla
- dan 3 lainnya
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.